Goldstein Advisors LLC raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 19.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,425 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Goldstein Advisors LLC’s holdings in Xeris Biopharma were worth $87,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in XERS. Vanguard Group Inc. increased its stake in Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after purchasing an additional 519,897 shares during the last quarter. NEA Management Company LLC purchased a new position in shares of Xeris Biopharma during the first quarter worth approximately $926,000. Renaissance Technologies LLC grew its position in shares of Xeris Biopharma by 33.9% during the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock worth $3,041,000 after acquiring an additional 342,300 shares during the last quarter. Rosalind Advisors Inc. grew its position in shares of Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock worth $7,020,000 after acquiring an additional 300,000 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Xeris Biopharma by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock worth $964,000 after acquiring an additional 80,015 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.
Xeris Biopharma Price Performance
NASDAQ:XERS opened at $3.20 on Friday. The firm’s fifty day moving average price is $2.87 and its 200 day moving average price is $2.40. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.39. The firm has a market cap of $474.42 million, a price-to-earnings ratio of -6.81 and a beta of 2.76.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Xeris Biopharma in a research report on Thursday, August 15th.
Check Out Our Latest Research Report on Xeris Biopharma
About Xeris Biopharma
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
- Five stocks we like better than Xeris Biopharma
- High Flyers: 3 Natural Gas Stocks for March 2022
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Retail Stocks Investing, Explained
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.